Top Biotech Stocks with Massive Upside and Breakthrough Potential

The biotech industry is experiencing significant growth, particularly in the obesity drug market, projected to reach $200 billion by 2031. Emerging companies like Viking Therapeutics and Corbus Pharmaceuticals are gaining attention for their promising therapies. Viking's VK2735 and VK2809 drugs show potential in obesity and NASH treatment, while Corbus's CRB-701 and CRB-913 target cancer and obesity. Both companies have received "Strong Buy" ratings from analysts, with Viking's stock having a 122.7% upside potential and Corbus's a 283.5% upside, according to Piper Sandler.